Why the study?
Iron deficiency affects approximately 50% of patients with symptomatic heart failure and is linked to worse functional capacity, quality of life, and mortality, while clinical trial evidence guiding iron repletion strategies is rapidly expanding.
Answers are grounded in this paper and cite their sources.
This Heart Failure Society of America scientific statement synthesizes the definition, epidemiology, pathophysiology, and clinical trial evidence for iron repletion in heart failure, where iron deficiency affects roughly 50% of symptomatic patients.
Iron deficiency is present in approximately 50% of patients with symptomatic heart failure and is independently associated with worse functional capacity, lower quality of life and increased mortality. The purpose of this document is to summarize current knowledge of how iron deficiency is defined in heart failure, its epidemiology and pathophysiology, as well as pharmacological considerations for repletion strategies. This document also summarizes the rapidly expanding array of clinical trial evidence informing when, how, and in whom to consider iron repletion.
No takes yet. Share an insight, caveat, or question.
Beavers et al. (2023) conducted a review in Iron deficiency in symptomatic heart failure. Iron repletion was evaluated. Iron deficiency affects ~50% of patients with symptomatic heart failure and is independently associated with worse functional capacity, lower quality of life, and increased mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: